Pentoxifylline (Tablets, Capsules, Solution, Concentrate) Instructions for Use

Instructions
Dosage forms

ATC Code

C04AD03 (Pentoxifylline)

Active Substance

Pentoxifylline (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Drug improving microcirculation. Angioprotector

Pharmacotherapeutic Group

Peripheral vasodilators; purine derivatives

Pharmacological Action

A microcirculation-improving agent, angioprotector, dimethylxanthine derivative. Pentoxifylline reduces blood viscosity, causes platelet disaggregation, increases the elasticity of erythrocytes (by acting on pathologically altered erythrocyte deformability), improves microcirculation and increases the concentration of oxygen in tissues.

It increases the concentration of cAMP in platelets and ATP in erythrocytes with simultaneous saturation of the energy potential, which in turn leads to vasodilation, a decrease in total peripheral vascular resistance, an increase in stroke volume and minute volume of blood without a significant change in heart rate.

By dilating the coronary arteries, it increases oxygen delivery to the myocardium; by dilating the pulmonary vessels, it improves blood oxygenation. It increases the tone of the respiratory muscles (intercostal muscles and diaphragm).

Intravenous administration, along with the above action, leads to enhanced collateral circulation, an increase in the volume of blood flowing per unit cross-section.

It increases the concentration of ATP in the brain and has a beneficial effect on the bioelectrical activity of the CNS. It improves microcirculation in areas of impaired blood supply.

In occlusive lesions of peripheral arteries (intermittent claudication), it leads to an increase in walking distance, elimination of nocturnal calf muscle cramps and pain at rest.

Pharmacokinetics

After oral administration, it is well absorbed from the gastrointestinal tract. There is a slight metabolism during the first pass through the liver. It binds to erythrocyte membranes. It undergoes biotransformation first in erythrocytes, then in the liver. Some metabolites are active. The T_1/2 of the unchanged substance from plasma is 0.4-0.8 hours, for metabolites – 1-1.6 hours. After 24 hours, most of the dose is excreted in the urine as metabolites, a smaller part (about 4%) – through the intestines.

The elimination of pentoxifylline is reduced in elderly patients and in patients with liver diseases.

Indications

Peripheral circulation disorders (including intermittent claudication) associated with chronic occlusive circulatory disorders in the arterial vessels of the lower extremities. Ischemic cerebrovascular accident, ischemic stroke and post-stroke conditions; cerebral atherosclerosis (dizziness, headache, memory impairment, sleep disorders), dyscirculatory encephalopathy, viral neuroinfection (prevention of possible microcirculation disorders). Coronary artery disease, condition after myocardial infarction. Diabetic angiopathy. Acute circulatory disorders in the retina and choroid, acute ischemic optic neuropathy. Otosclerosis, degenerative changes against the background of pathology of the vessels of the inner ear with gradual hearing loss. Chronic obstructive pulmonary disease, bronchial asthma. Impotence of vascular origin.

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
A89	Viral infection of the central nervous system, unspecified
F07	Personality and behavioral disorders due to disease, damage or dysfunction of the brain
G45	Transient cerebral ischemic attacks [TIAs] and related syndromes
G93.4	Unspecified encephalopathy
H34	Retinal vascular occlusions
H35.0	Background retinopathy and retinal vascular changes
H36.0	Diabetic retinopathy
H47.0	Disorders of optic nerve, not elsewhere classified (including ischemic optic neuropathy)
H80	Otosclerosis
H93.0	Degenerative and vascular disorders of ear
I20	Angina pectoris
I21	Acute myocardial infarction
I63	Cerebral infarction
I67.2	Cerebral atherosclerosis
I69	Sequelae of cerebrovascular diseases
I73.0	Raynaud's syndrome
I73.1	Obliterative thromboangiitis [Buerger's disease]
I73.8	Other specified peripheral vascular diseases
I73.9	Peripheral vascular disease, unspecified (including intermittent claudication, arterial spasm)
I79.2	Peripheral angiopathy in diseases classified elsewhere (including diabetic angiopathy)
J44	Other chronic obstructive pulmonary disease
J45	Asthma
N48.4	Impotence of organic origin

ICD-11 code	Indication
1C8Z	Viral infections of the central nervous system, unspecified
4A44.8	Thromboangiitis obliterans
6E68	Secondary emotionally labile personality disorder
6E6Z	Unspecified secondary mental or behavioral syndromes
8B10.Z	Transient ischemic attack, unspecified
8B11	Cerebral ischemic stroke
8B25.Z	Sequelae of cerebrovascular disease, unspecified
8E47	Encephalopathy, not elsewhere classified
8E4A.0	Paraneoplastic or autoimmune disorders of the central nervous system, including brain and spinal cord
8E63	Post-cardiopulmonary bypass encephalopathy
9B71.0Z	Diabetic retinopathy, unspecified
9B74.Z	Retinal vascular occlusion, unspecified
9B78.1Z	Background retinopathy and retinal vascular changes, unspecified
9C40.Z	Disorders of optic nerve, unspecified
AB33	Otosclerosis
AB71	Degenerative or vascular disorders of the ear
BA40.Z	Angina pectoris, unspecified
BA41.Z	Acute myocardial infarction, unspecified
BD42.0	Raynaud's disease
BD42.1	Raynaud's syndrome
BD42.Z	Raynaud's phenomenon, unspecified
BD4Z	Chronic obliterative arterial diseases, unspecified
BD53.Y	Other specified secondary involvement of arteries and arterioles
BD55	Asymptomatic stenosis of intracranial or extracranial artery
BD5Z	Diseases of arteries or arterioles, unspecified
CA22.Z	Chronic obstructive pulmonary disease, unspecified
CA23	Asthma
EG00	Dilation of skin vessels of the extremities
HA01.1Z	Male erectile dysfunction, unspecified
MB40.7	Acroparesthesia

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Tablets

The duration of treatment and the dosing regimen for Pentoxifylline are established individually by the attending physician, depending on the clinical picture of the disease and the therapeutic effect achieved.

The drug is taken orally immediately after meals, without chewing, with a sufficient amount of liquid.

For adults, the drug is prescribed starting from 200 mg 3 times/day.

Prolonged-release dosage forms are prescribed 2 times/day. The course of treatment is 2-3 weeks or more.

Solution

The drug can be administered intravenously, intra-arterially.

Intravenous drip infusion is administered slowly at a dose of 100 mg in 250-500 ml of isotonic sodium chloride solution or in a 5% glucose solution (duration of administration – 90-180 min); intra-arterially – first at a dose of 100 mg in 20-50 ml of isotonic sodium chloride solution, and on subsequent days – 200-300 mg in 30-50 ml of solvent.

Rate of administration: 100 mg (5 ml of 2% pentoxifylline solution) over 10 min.

Capsules, Concentrate

Used intra-arterially (bolus or drip), intravenously (bolus or drip), intramuscularly, orally. The dose and treatment regimen are established individually.

Adverse Reactions

From the CNS headache, dizziness; anxiety, sleep disorders, convulsions.

Dermatological reactions skin hyperemia, flushing of the skin of the face and upper chest, edema, increased brittleness of nails.

From the digestive system dry mouth, decreased appetite, intestinal atony, exacerbation of cholecystitis, cholestatic hepatitis, increased activity of hepatic transaminases and alkaline phosphatase.

From the organ of vision visual impairment, scotoma.

From the cardiovascular system tachycardia, arrhythmia, cardialgia, progression of angina, decreased blood pressure.

From the hematopoietic system thrombocytopenia, leukopenia, pancytopenia.

From the blood coagulation system hypofibrinogenemia, bleeding from skin vessels, mucous membranes, stomach, intestines.

Allergic reactions itching, skin hyperemia, urticaria, angioedema, anaphylactic shock.

Contraindications

Acute myocardial infarction, porphyria, massive bleeding, hemorrhagic stroke, retinal hemorrhage, pregnancy, lactation period. For intravenous administration (additionally) – arrhythmias, severe atherosclerosis of coronary or cerebral arteries, uncontrolled arterial hypotension.

Hypersensitivity to pentoxifylline and other xanthine derivatives.

Use in Pregnancy and Lactation

Adequate and well-controlled clinical studies on the safety of pentoxifylline use during pregnancy have not been conducted.

Pentoxifylline and its metabolites are excreted in breast milk. If use during lactation is necessary, breastfeeding should be discontinued.

Use in Hepatic Impairment

In severe liver function disorders, correction of the pentoxifylline dosing regimen is required.

Use in Renal Impairment

In renal function disorders, correction of the pentoxifylline dosing regimen is required.

Pediatric Use

Use with caution in children and adolescents under 18 years of age (efficacy and safety have not been studied).

Special Precautions

Use with caution in cases of labile blood pressure (tendency to arterial hypotension), chronic heart failure, gastric and duodenal ulcer (for oral administration), after recent surgical interventions, in hepatic and/or renal failure, in children and adolescents under 18 years of age (efficacy and safety have not been studied).

In cases of renal impairment or severe hepatic impairment, correction of the pentoxifylline dosing regimen is required.

Blood pressure levels should be monitored during treatment.

With simultaneous use with antihypertensive agents, insulin, oral hypoglycemic drugs, a reduction in the dose of pentoxifylline may be required.

With simultaneous use with anticoagulants, blood coagulation parameters should be carefully monitored.

Drug Interactions

Pentoxifylline may potentiate the effect of antihypertensive drugs.

Against the background of parenteral use of pentoxifylline in high doses, an enhancement of the hypoglycemic effect of insulin in patients with diabetes mellitus is possible.

With simultaneous use with ketorolac, an increased risk of bleeding and/or increased prothrombin time is possible; with meloxicam – an increased risk of bleeding; with sympatholytics, ganglion blockers and vasodilators – a decrease in blood pressure is possible; with heparin, fibrinolytic drugs – enhancement of the anticoagulant effect.

Cimetidine significantly increases the plasma concentration of pentoxifylline, therefore, with simultaneous use, the likelihood of adverse effects may increase.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Pentoxifylline [Shreya Life Sciences, Pvt.Ltd. (India)]
Retard tablets, film-coated, 400 mg: 10, 20, 30, 40, 50, 60, 80, 100, 120, 200 pcs.
Enteric-coated tablets, 100 mg: 10, 20, 30, 40, 50, 60, 80, 100, 120, or 200 pcs.

Marketing Authorization Holder

Shreya Life Sciences, Pvt.Ltd. (India)

Dosage Forms

	Pentoxifylline	Retard tablets, film-coated, 400 mg: 10, 20, 30, 40, 50, 60, 80, 100, 120, 200 pcs.
		Enteric-coated tablets, 100 mg: 10, 20, 30, 40, 50, 60, 80, 100, 120, or 200 pcs.

Dosage Form, Packaging, and Composition

Enteric-coated tablets pink, film-coated; round, biconvex.

	1 tab.
Pentoxifylline	100 mg

Excipients: microcrystalline cellulose, dibasic calcium phosphate, polyvinylpyrrolidone, magnesium stearate, sodium croscarmellose, talc.

Coating composition: methacrylic acid copolymer, diethyl phthalate, titanium dioxide, carmoisine lake.

10 pcs. – blisters (6) – cardboard packs.

Retard tablets, film-coated pink, capsule-shaped, with a break line on one side.

	1 tab.
Pentoxifylline	400 mg

Excipients: ethylcellulose, dibasic calcium phosphate, magnesium stearate, talc.

Coating composition: titanium dioxide, hypromellose, diethyl phthalate, carmoisine lake.

10 pcs. – blisters (2) – cardboard packs.

Pentoxifylline [Shreya Life Sciences, Pvt.Ltd. (India)]
Solution for injection 20 mg/1 ml: amp. 3, 5, 6, 9, 10, 12, 15, 20, 30, or 40 pcs.
Solution for injection 40 mg/2 ml: amp. 3, 5, 6, 9, 10, 12, 15, 20, 30, or 40 pcs.
Solution for injection 100 mg/5 ml: amp. 3, 5, 6, 9, 10, 12, 15, 20, 30, or 40 pcs.

Marketing Authorization Holder

Shreya Life Sciences, Pvt.Ltd. (India)

Dosage Forms

	Pentoxifylline	Solution for injection 20 mg/1 ml: amp. 3, 5, 6, 9, 10, 12, 15, 20, 30, or 40 pcs.
		Solution for injection 40 mg/2 ml: amp. 3, 5, 6, 9, 10, 12, 15, 20, 30, or 40 pcs.
		Solution for injection 100 mg/5 ml: amp. 3, 5, 6, 9, 10, 12, 15, 20, 30, or 40 pcs.

Dosage Form, Packaging, and Composition

Solution for injection clear, colorless or slightly yellowish.

	1 ml
Pentoxifylline	20 mg

Excipients: sodium chloride, water for injections.

1 ml – ampoules (5) – polyethylene trays (1) – cardboard boxes.

Solution for injection clear, colorless or slightly yellowish.

	1 ml	1 amp.
Pentoxifylline	20 mg	40 mg

Excipients: sodium chloride, water for injections.

2 ml – ampoules (5) – polyethylene trays (1) – cardboard boxes.

Solution for injection clear, colorless or slightly yellowish.

	1 ml	1 amp.
Pentoxifylline	20 mg	100 mg

Excipients: sodium chloride, water for injections.

5 ml – ampoules (5) – polyethylene trays (1) – cardboard boxes.

Pentoxifylline [Alvils, LLC (Russia)]
Concentrate for solution for infusion 20 mg/1 ml: 5 ml amp. 5 or 10 pcs.

Marketing Authorization Holder

Alvils, LLC (Russia)

Manufactured By

Northeast Pharmaceutical Group Co., Ltd (China)

Dosage Form

Pentoxifylline

Concentrate for solution for infusion 20 mg/1 ml: 5 ml amp. 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Concentrate for solution for infusion in the form of a clear, colorless or slightly colored liquid.

	1 ml
Pentoxifylline	20 mg

Excipients: water for injections – up to 1 ml.

5 ml – ampoules of colorless glass (5) – blisters (1) – cardboard packs.
5 ml – ampoules of colorless glass (5) – blisters (2) – cardboard packs.
5 ml – ampoules of colorless glass (10) – blisters (1) – cardboard packs.

Pentoxifylline [Atoll LLC (Russia)]
Enteric-coated tablets, 100 mg: 10, 14, 20, 25, 28, 30, 40, 42, 50, 56, 60, 70, 75, 84, 90, 100, 120, 125, 150, 168, 180, 300, or 360 pcs.

Marketing Authorization Holder

Atoll LLC (Russia)

Manufactured By

Ozon, LLC (Russia)

Dosage Form

Pentoxifylline

Enteric-coated tablets, 100 mg: 10, 14, 20, 25, 28, 30, 40, 42, 50, 56, 60, 70, 75, 84, 90, 100, 120, 125, 150, 168, 180, 300, or 360 pcs.

Dosage Form, Packaging, and Composition

Enteric-coated tablets white or almost white in color; round, cylindrical, biconvex in shape; on the cross-section, a film coating and a core of white or almost white color are visible.

	1 tab.
Pentoxifylline	100 mg

Excipients: lactose monohydrate (milk sugar) – 53.42 mg, potato starch – 18 mg, povidone K25 – 7.2 mg, methylcellulose – 0.48 mg, magnesium stearate – 0.9 mg.

Enteric coating composition: acryl-iz white 93A – 7.2 mg, including: methacrylic acid and ethyl acrylate copolymer (1:1) – 4.752 mg, talc – 1.188 mg, titanium dioxide – 1.08 mg, colloidal silicon dioxide – 0.072 mg, sodium bicarbonate – 0.072 mg, sodium lauryl sulfate – 0.036 mg, triethyl citrate – 0.8 mg.

10 pcs. – contour cell blisters (1) – cardboard packs.
10 pcs. – contour cell blisters (2) – cardboard packs.
10 pcs. – contour cell blisters (3) – cardboard packs.
10 pcs. – contour cell blisters (4) – cardboard packs.
10 pcs. – contour cell blisters (5) – cardboard packs.
10 pcs. – contour cell blisters (6) – cardboard packs.
10 pcs. – contour cell blisters (12) – cardboard packs.
14 pcs. – contour cell blisters (1) – cardboard packs.
14 pcs. – contour cell blisters (2) – cardboard packs.
14 pcs. – contour cell blisters (3) – cardboard packs.
14 pcs. – contour cell blisters (4) – cardboard packs.
14 pcs. – contour cell blisters (5) – cardboard packs.
14 pcs. – contour cell blisters (6) – cardboard packs.
14 pcs. – contour cell blisters (12) – cardboard packs.
25 pcs. – contour cell blisters (1) – cardboard packs.
25 pcs. – contour cell blisters (2) – cardboard packs.
25 pcs. – contour cell blisters (3) – cardboard packs.
25 pcs. – contour cell blisters (4) – cardboard packs.
25 pcs. – contour cell blisters (5) – cardboard packs.
25 pcs. – contour cell blisters (6) – cardboard packs.
25 pcs. – contour cell blisters (12) – cardboard packs.
30 pcs. – contour cell blisters (1) – cardboard packs.
30 pcs. – contour cell blisters (2) – cardboard packs.
30 pcs. – contour cell blisters (3) – cardboard packs.
30 pcs. – contour cell blisters (4) – cardboard packs.
30 pcs. – contour cell blisters (5) – cardboard packs.
30 pcs. – contour cell blisters (6) – cardboard packs.
30 pcs. – contour cell blisters (12) – cardboard packs.
10 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
20 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
30 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
40 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
50 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
60 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
100 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
120 pcs. – polyethylene terephthalate jars (1) – cardboard packs.

Pentoxifylline [Atoll LLC (Russia)]
Concentrate for solution for infusion 20 mg/ml: 5 ml amp. 5 or 10 pcs.

Marketing Authorization Holder

Atoll LLC (Russia)

Manufactured By

Ozon, LLC (Russia)

Dosage Form

Pentoxifylline

Concentrate for solution for infusion 20 mg/ml: 5 ml amp. 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Concentrate for solution for infusion in the form of a clear, white or slightly colored liquid.

	1 ml
Pentoxifylline	20 mg

Excipients: sodium chloride – 6 mg, sodium dihydrogen phosphate dihydrate – 1 mg, sodium hydroxide solution 0.1 M – to pH 6.0-8.0, water for injection – to 1 ml.

5 ml – ampoules of colorless glass (5) – contour cell blisters (1) – cardboard packs.
5 ml – ampoules of colorless glass (5) – contour cell blisters (2) – cardboard packs.
5 ml – ampoules of colorless glass (5) – cardboard trays (1) – cardboard packs.
5 ml – ampoules of colorless glass (5) – cardboard trays (2) – cardboard packs.

Pentoxifylline [Belarusian-Dutch Joint Venture "FARMLAND", LLC (Republic of Belarus)]
Solution for infusion 2 mg/ml: container 100 ml

Marketing Authorization Holder

Belarusian-Dutch Joint Venture "FARMLAND", LLC (Republic of Belarus)

Dosage Form

Pentoxifylline

Solution for infusion 2 mg/ml: container 100 ml

Dosage Form, Packaging, and Composition

Solution for infusion	1 ml
Pentoxifylline	2 mg

Excipients: sodium chloride 9 mg, water for injection to 1 ml.

100 ml – polymer containers (1) – polyethylene bags.

Pentoxifylline [Binnopharm JSC (Russia)]
Solution for intravenous injection 100 mg/5 ml: amp. 5 or 10 pcs.

Marketing Authorization Holder

Binnopharm JSC (Russia)

Dosage Form

Pentoxifylline

Solution for intravenous injection 100 mg/5 ml: amp. 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Concentrate for preparation of solution for intravenous and intra-arterial administration	1 ml	1 amp.
Pentoxifylline	20 mg	100 mg

5 ml – ampoules (10) – cardboard packs.
5 ml – ampoules (5) – contour cell blisters (2) – cardboard packs.
5 ml – ampoules (5) – contour cell blisters (1) – cardboard packs.

Pentoxifylline [Biosintez, PJSC (Russia)]
Enteric-coated tablets, 100 mg: 20, 30, or 60 pcs.

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Pentoxifylline

Enteric-coated tablets, 100 mg: 20, 30, or 60 pcs.

Dosage Form, Packaging, and Composition

Enteric-coated tablets pink in color, round, biconvex.

	1 tab.
Pentoxifylline	100 mg

Excipients: lactose, water-soluble methylcellulose MC 16, calcium stearate, povidone, potato starch.

Concentrate for solution for infusion in the form of a clear, colorless or slightly yellowish liquid.

	1 ml
Pentoxifylline	20 mg

Excipients: sodium chloride, sodium dihydrogen phosphate dihydrate (sodium phosphate monobasic dihydrate), sodium hydroxide solution 1M, water for injection – to 1 ml.

5 ml – ampoules of neutral glass (5) – contour cell blisters (1) – cardboard packs.
5 ml – ampoules of neutral glass (5) – contour cell blisters (2) – cardboard packs.

Pentoxifylline [Velpharm, LLC (Russia)]
Enteric-coated tablets, 100 mg: 10, 14, 20, 28, 30, 40, 42, 50, 56, 60, 70, 80, 84, 90, 98, 100, 112, 126, or 140 pcs.

Marketing Authorization Holder

Velpharm, LLC (Russia)

Dosage Form

Pentoxifylline

Enteric-coated tablets, 100 mg: 10, 14, 20, 28, 30, 40, 42, 50, 56, 60, 70, 80, 84, 90, 98, 100, 112, 126, or 140 pcs.

Dosage Form, Packaging, and Composition

Enteric-coated tablets white in color, round, biconvex; on the cross-section, the core is white or almost white.

	1 tab.
Pentoxifylline	100 mg

Excipients: lactose monohydrate (milk sugar), potato starch, talc, colloidal silicon dioxide (aerosil), magnesium stearate.

Coating composition[dry mixture for film coating, containing methacrylic acid and ethyl acrylate copolymer 1:1, talc, titanium dioxide, colloidal silicon dioxide (aerosil), sodium bicarbonate, sodium lauryl sulfate], triethyl citrate.

10 pcs. – contour cell blisters (1) – cardboard packs.
10 pcs. – contour cell blisters (2) – cardboard packs.
10 pcs. – contour cell blisters (3) – cardboard packs.
10 pcs. – contour cell blisters (4) – cardboard packs.
10 pcs. – contour cell blisters (5) – cardboard packs.
10 pcs. – contour cell blisters (6) – cardboard packs.
10 pcs. – contour cell blisters (7) – cardboard packs.
10 pcs. – contour cell blisters (8) – cardboard packs.
10 pcs. – contour cell blisters (9) – cardboard packs.
10 pcs. – contour cell blisters (10) – cardboard packs.
14 pcs. – contour cell blisters (1) – cardboard packs.
14 pcs. – contour cell blisters (2) – cardboard packs.
14 pcs. – contour cell blisters (3) – cardboard packs.
14 pcs. – contour cell blisters (4) – cardboard packs.
14 pcs. – contour cell blisters (5) – cardboard packs.
14 pcs. – contour cell blisters (6) – cardboard packs.
14 pcs. – contour cell blisters (7) – cardboard packs.
14 pcs. – contour cell blisters (8) – cardboard packs.
14 pcs. – contour cell blisters (9) – cardboard packs.
14 pcs. – contour cell blisters (10) – cardboard packs.
10 pcs. – jars – cardboard packs.
20 pcs. – jars – cardboard packs.
30 pcs. – jars – cardboard packs.
40 pcs. – jars – cardboard packs.
50 pcs. – jars – cardboard packs.
60 pcs. – jars – cardboard packs.
70 pcs. – jars – cardboard packs.
80 pcs. – jars – cardboard packs.
90 pcs. – jars – cardboard packs.
100 pcs. – jars – cardboard packs.

Pentoxifylline [Grotex, LLC (Russia)]
Concentrate for solution for infusion 20 mg/ml: 5 ml amp. 10 pcs.

Marketing Authorization Holder

Grotex, LLC (Russia)

Manufactured By

Grotex, LLC (Russia)

Dosage Form

Pentoxifylline

Concentrate for solution for infusion 20 mg/ml: 5 ml amp. 10 pcs.

Dosage Form, Packaging, and Composition

Concentrate for solution for infusion in the form of a clear, colorless or with a yellowish tint liquid.

	1 ml
Pentoxifylline	20 mg

Excipients: sodium chloride – 6 mg, sodium dihydrogen phosphate dihydrate – 1 mg, sodium hydroxide solution 1M – to pH 6.0 – 8.0, water for injection – to 1 ml.

5 ml – polyethylene ampoules (10) – cardboard packs.

Pentoxifylline [Dalkhimpharm, JSC (Russia)]
Solution for injection 20 mg/ml: amp. 10 pcs.

Marketing Authorization Holder

Dalkhimpharm, JSC (Russia)

Dosage Form

Pentoxifylline

Solution for injection 20 mg/ml: amp. 10 pcs.

Dosage Form, Packaging, and Composition

Solution for injection clear, colorless or slightly yellowish.

	1 ml
Pentoxifylline	20 mg

Concentrate for solution for intravenous and intra-arterial administration as a clear, colorless or light yellow liquid.

	1 ml
Pentoxifylline	20 mg

Excipients: sodium chloride – 6 mg, sodium dihydrogen phosphate dihydrate – 1 mg, sodium hydroxide solution 0.1 M – to pH 6.0-8.0, water for injection – up to 1 ml.

5 ml – polymer ampoules (5) – cardboard packs.
5 ml – polymer ampoules (10) – cardboard packs.
10 ml – polymer ampoules (5) – cardboard packs.
10 ml – polymer ampoules (10) – cardboard packs.

Pentoxifylline [Uralbiopharm, JSC (Russia)]
Enteric-coated tablets, 100 mg: 10, 20, 30, 40, 50, or 60 pcs.

Marketing Authorization Holder

Uralbiopharm, JSC (Russia)

Dosage Form

Pentoxifylline

Enteric-coated tablets, 100 mg: 10, 20, 30, 40, 50, or 60 pcs.

Dosage Form, Packaging, and Composition

Enteric-coated tablets	1 tab.
Pentoxifylline	100 mg

10 pcs. – blisters (6) – cardboard packs.
60 pcs. – dark glass jars (1) – cardboard packs.
10 pcs. – blisters (1) – cardboard packs.
10 pcs. – blisters (2) – cardboard packs.
10 pcs. – blisters (3) – cardboard packs.
10 pcs. – blisters (4) – cardboard packs.
10 pcs. – blisters (5) – cardboard packs.
20 pcs. – dark glass jars (1) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
40 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.

Pentoxifylline [Pharmproekt, JSC (Russia)]
Enteric-coated film-coated tablets, 100 mg: 60 pcs.

Marketing Authorization Holder

Pharmproekt, JSC (Russia)

Dosage Form

Pentoxifylline

Enteric-coated film-coated tablets, 100 mg: 60 pcs.

Dosage Form, Packaging, and Composition

Enteric-coated film-coated tablets	1 tab.
Pentoxifylline	100 mg

60 pcs. – polymer bottles (1) – cardboard packs.
10 pcs. – blisters (6) – cardboard packs.

Pentoxifylline Sandoz [Sandoz, d.d. (Slovenia)]
Extended-release tablets 600 mg: 30 or 50 pcs.

Marketing Authorization Holder

Sandoz, d.d. (Slovenia)

Manufactured By

Salutas Pharma, GmbH (Germany)

Dosage Form

Pentoxifylline Sandoz

Extended-release tablets 600 mg: 30 or 50 pcs.

Dosage Form, Packaging, and Composition

Extended-release tablets white, oblong, biconvex, with a score on both sides.

	1 tab.
Pentoxifylline	600 mg

Excipients: copovidone – 60 mg, hypromellose K 15 M – 32 mg, hypromellose K 100 M – 46 mg, talc – 14 mg, magnesium stearate – 8 mg.

10 pcs. – blisters (3) – cardboard packs.
10 pcs. – blisters (5) – cardboard packs.

Pentoxifylline Velpharm [Velpharm, LLC (Russia)]
Enteric-coated film-coated tablets 100 mg

Marketing Authorization Holder

Velpharm, LLC (Russia)

Dosage Form

Pentoxifylline Velpharm

Enteric-coated film-coated tablets 100 mg

Dosage Form, Packaging, and Composition

Enteric-coated film-coated tablets

	1 tab.
Pentoxifylline	100 mg

10 pcs. – jars – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packs – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packs (10 pcs.) – cardboard packs (100 pcs.) – By prescription
10 pcs. – contour cell packs (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – contour cell packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – contour cell packs (4 pcs.) – cardboard packs (40 pcs.) – By prescription
10 pcs. – contour cell packs (5 pcs.) – cardboard packs (50 pcs.) – By prescription
10 pcs. – contour cell packs (6 pcs.) – cardboard packs (60 pcs.) – By prescription
10 pcs. – contour cell packs (7 pcs.) – cardboard packs (70 pcs.) – By prescription
10 pcs. – contour cell packs (8 pcs.) – cardboard packs (80 pcs.) – By prescription
10 pcs. – contour cell packs (9 pcs.) – cardboard packs (90 pcs.) – By prescription
100 pcs. – jars – cardboard packs (100 pcs.) – By prescription
14 pcs. – contour cell packs – cardboard packs (14 pcs.) – By prescription
14 pcs. – contour cell packs (10 pcs.) – cardboard packs (140 pcs.) – By prescription
14 pcs. – contour cell packs (2 pcs.) – cardboard packs (28 pcs.) – By prescription
14 pcs. – contour cell packs (3 pcs.) – cardboard packs (42 pcs.) – By prescription
14 pcs. – contour cell packs (4 pcs.) – cardboard packs (56 pcs.) – By prescription
14 pcs. – contour cell packs (5 pcs.) – cardboard packs (70 pcs.) – By prescription
14 pcs. – contour cell packs (6 pcs.) – cardboard packs (84 pcs.) – By prescription
14 pcs. – contour cell packs (7 pcs.) – cardboard packs (98 pcs.) – By prescription
14 pcs. – contour cell packs (8 pcs.) – cardboard packs (112 pcs.) – By prescription
14 pcs. – contour cell packs (9 pcs.) – cardboard packs (126 pcs.) – By prescription
20 pcs. – jars – cardboard packs (20 pcs.) – By prescription
30 pcs. – jars – cardboard packs (30 pcs.) – By prescription
40 pcs. – jars – cardboard packs (40 pcs.) – By prescription
50 pcs. – jars – cardboard packs (50 pcs.) – By prescription
60 pcs. – jars – cardboard packs (60 pcs.) – By prescription
70 pcs. – jars – cardboard packs (70 pcs.) – By prescription
80 pcs. – jars – cardboard packs (80 pcs.) – By prescription
90 pcs. – jars – cardboard packs (90 pcs.) – By prescription

Pentoxifylline-Akri^® [Akrikhin Chemical and Pharmaceutical Plant, JSC (Russia)]
Film-coated tablets, 100 mg: 60 pcs.

Marketing Authorization Holder

Akrikhin Chemical and Pharmaceutical Plant, JSC (Russia)

Dosage Form

Pentoxifylline-Akri^®

Film-coated tablets, 100 mg: 60 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets	1 tab.
Pentoxifylline	100 mg

10 pcs. – contour cell packs (6) – cardboard packs.

Pentoxifylline-Darnitsa [Darnitsa Pharmaceutical Firm, PJSC (Ukraine)]
Tablets 200 mg: 10, 20, 30, 40, or 50 pcs.

Marketing Authorization Holder

Darnitsa Pharmaceutical Firm, PJSC (Ukraine)

Dosage Form

Pentoxifylline-Darnitsa

Tablets 200 mg: 10, 20, 30, 40, or 50 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Pentoxifylline	200 mg

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.

Pentoxifylline-Darnitsa [Darnitsa Pharmaceutical Firm, PJSC (Ukraine)]
Concentrate for solution for intravenous and intra-arterial administration 100 mg/5 ml: amp. 10 pcs.

Marketing Authorization Holder

Darnitsa Pharmaceutical Firm, PJSC (Ukraine)

Dosage Form

Pentoxifylline-Darnitsa

Concentrate for solution for intravenous and intra-arterial administration 100 mg/5 ml: amp. 10 pcs.

Dosage Form, Packaging, and Composition

Concentrate for solution for intravenous and intra-arterial administration	1 ml	1 amp.
Pentoxifylline	20 mg	100 mg

5 ml – ampoules (10) – cardboard packs.

Pentoxifylline-Eskom [Mir Chemical and Pharmaceutical Concern, LLC (Russia)]
Concentrate for solution for injection 100 mg/5 ml: amp. 5, 10, or 20 pcs.

Marketing Authorization Holder

Mir Chemical and Pharmaceutical Concern, LLC (Russia)

Dosage Form

Pentoxifylline-Eskom

Concentrate for solution for injection 100 mg/5 ml: amp. 5, 10, or 20 pcs.

Dosage Form, Packaging, and Composition

Concentrate for solution for injection	1 ml	1 amp.
Pentoxifylline	20 mg	100 mg

5 ml – ampoules (10) – cardboard packs.
5 ml – ampoules (10) – contour plastic packs (1) – cardboard packs.
5 ml – ampoules (10) – contour plastic packs (2) – cardboard packs.
5 ml – ampoules (5) – contour plastic packs (2) – cardboard packs.
5 ml – ampoules (5) – contour plastic packs (1) – cardboard packs.

Pentoxifylline-FPO^® [FP Obolenskoe, JSC (Russia)]
Enteric-coated tablets 100 mg: 10, 20, 30, 40, 60, or 120 pcs.

Marketing Authorization Holder

FP Obolenskoe, JSC (Russia)

Dosage Form

Pentoxifylline-FPO^®

Enteric-coated tablets 100 mg: 10, 20, 30, 40, 60, or 120 pcs.

Dosage Form, Packaging, and Composition

Enteric-coated tablets	1 tab.
Pentoxifylline	100 mg

Pentoxifylline-MIC [Minskintercaps Up (Republic Of Belarus)]
Capsules 200 mg: 10, 40, or 50 pcs.

Marketing Authorization Holder

Minskintercaps Up (Republic Of Belarus)

Dosage Form

Pentoxifylline-MIC

Capsules 200 mg: 10, 40, or 50 pcs.

Dosage Form, Packaging, and Composition

Capsules	1 caps.
Pentoxifylline	200 mg

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.

Pentoxifylline-Teva [Teva Pharmaceutical Industries, Ltd. (Israel)]
Retard tablets, film-coated, 400 mg: 20 or 90 pcs.